GPD1 Inhibitors
GPD1 inhibitors, short for glycerol-3-phosphate dehydrogenase 1 inhibitors, belong to a distinctive class of compounds that specifically target the enzymatic activity of glycerol-3-phosphate dehydrogenase 1 (GPD1). GPD1 is a crucial enzyme involved in glycerolipid metabolism, playing a pivotal role in the conversion of dihydroxyacetone phosphate to glycerol-3-phosphate. This enzymatic conversion is a key step in both glycerolipid biosynthesis and glycerolipid catabolism, making GPD1 a central player in cellular lipid homeostasis. The inhibition of GPD1 by compounds falling under the GPD1 inhibitors class is a finely tuned process that modulates the delicate balance of lipid metabolism within the cell.
GPD1 inhibitors exhibit structural diversity, and their design often involves targeting the active site of the GPD1 enzyme. Small molecules and compounds with specific pharmacophores are synthesized to interact with key residues in the enzyme's active site, thereby impeding its catalytic function. The inhibition of GPD1 by these compounds results in a downstream impact on lipid-related pathways, influencing the cellular levels of glycerol-3-phosphate and other associated metabolites. The exploration of GPD1 inhibitors and their mechanism of action offers valuable insights into the regulation of lipid metabolism at the molecular level, contributing to a deeper understanding of cellular processes and potential avenues for further research in the field of biochemistry.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Metformin-d6, Hydrochloride | 1185166-01-1 | sc-218701 sc-218701A sc-218701B | 1 mg 5 mg 10 mg | $292.00 $822.00 $1540.00 | 1 | |
Metformin activates AMP-activated protein kinase (AMPK), which can subsequently inhibit lipogenesis, potentially reducing the availability of substrates for GPD1. | ||||||
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $41.00 | 9 | |
Fenofibrate activates peroxisome proliferator-activated receptor alpha (PPARα), leading to altered lipid metabolism that can decrease the substrate availability for GPD1. | ||||||
Nicotinamide | 98-92-0 | sc-208096 sc-208096A sc-208096B sc-208096C | 100 g 250 g 1 kg 5 kg | $44.00 $66.00 $204.00 $831.00 | 6 | |
Nicotinamide acts as a precursor for NAD+ and in high concentrations can inhibit sirtuins, which may alter NAD+/NADH ratio affecting GPD1's activity. | ||||||
GW 9662 | 22978-25-2 | sc-202641 | 5 mg | $70.00 | 30 | |
GW9662 is a PPARγ antagonist, which by inhibiting PPARγ, can alter the lipid metabolism, indirectly affecting the activity of GPD1. | ||||||
(+)-Etomoxir sodium salt | 828934-41-4 | sc-215009 sc-215009A | 5 mg 25 mg | $151.00 $506.00 | 3 | |
Etomoxir inhibits carnitine palmitoyltransferase-1 (CPT-1), which may reduce fatty acid oxidation, affecting the NAD+/NADH ratio and possibly the activity of GPD1. | ||||||
WY 14643 | 50892-23-4 | sc-203314 | 50 mg | $136.00 | 7 | |
WY-14643 is a PPARα agonist, which can modulate lipid metabolism and reduce the availability of glycerol-3-phosphate, the substrate for GPD1. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine affects lysosomal function and autophagy, which can lead to alterations in cellular metabolism potentially impacting the availability of GPD1 substrates. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that can affect various signaling pathways, potentially influencing the metabolic pathways where GPD1 is involved. | ||||||
Berberine | 2086-83-1 | sc-507337 | 250 mg | $92.00 | 1 | |
Berberine can activate AMPK and affect lipid metabolism, thereby potentially reducing substrate flow through pathways involving GPD1. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $55.00 $125.00 | 13 | |
Pioglitazone, a PPARγ agonist, can influence lipid metabolism and insulin sensitivity, which may indirectly affect GPD1 activity by altering substrate levels. | ||||||